Downloaded from Genbank (Table S5)
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Mass Emergence of the Tropical Swallowtail Moth Lyssa Zampa (Lepidoptera: Uraniidae: Uraniinae) in Singapore, with Notes on Its Partial Life History
20 TROP. LEPID. RES., 30(1): 20-27, 2020 JAIN & TEA: Mass emergence of Lyssa zampa Mass emergence of the tropical swallowtail moth Lyssa zampa (Lepidoptera: Uraniidae: Uraniinae) in Singapore, with notes on its partial life history Anuj Jain1,2, †,‡ and Yi-Kai Tea1,3,4 1Nature Society (Singapore), 510 Geylang Road, Singapore. 2Department of Biological Sciences, National University of Singapore, Singapore. 3School of Life and Environmental Sciences, University of Sydney, Sydney, Australia. 4Australian Museum Research Institute, 1 William Street, Sydney, New South Wales 2010, Australia. †Corresponding author: [email protected]; ‡Current affiliation: BirdLife International (Asia), #01-16/17, 354Tanglin Road, Singapore Date of issue online: 5 May 2020 Electronic copies (ISSN 2575-9256) in PDF format at: http://journals.fcla.edu/troplep; https://zenodo.org; archived by the Institutional Repository at the University of Florida (IR@UF), http://ufdc.ufl.edu/ufir;DOI : 10.5281/zenodo.3764165. © The author(s). This is an open access article distributed under the Creative Commons license CC BY-NC 4.0 (https://creativecommons.org/ licenses/by-nc/4.0/). Abstract: The tropical swallowtail uraniid moth Lyssa zampa is known to exhibit seasonal patterns of mass emergence throughout its range. These cyclical patterns of emergences are thought to correlate closely with oscillating host plant availability, as well as with interactions between herbivory and host plant defences. Because little has been reported concerning the biology of this species, the purpose of this paper is intended to serve as a starting point addressing the natural history of L. zampa in Singapore. Here we report on an instance of mass emergence of L. -
The Evolution, Diversity, and Host Associations of Rhabdoviruses Ben Longdon,1,* Gemma G
Virus Evolution, 2015, 1(1): vev014 doi: 10.1093/ve/vev014 Research article The evolution, diversity, and host associations of rhabdoviruses Ben Longdon,1,* Gemma G. R. Murray,1 William J. Palmer,1 Jonathan P. Day,1 Darren J Parker,2,3 John J. Welch,1 Darren J. Obbard4 and Francis M. Jiggins1 1 2 Department of Genetics, University of Cambridge, Cambridge, CB2 3EH, School of Biology, University of Downloaded from St Andrews, St Andrews, KY19 9ST, UK, 3Department of Biological and Environmental Science, University of Jyva¨skyla¨, Jyva¨skyla¨, Finland and 4Institute of Evolutionary Biology, and Centre for Immunity Infection and Evolution, University of Edinburgh, Edinburgh, EH9 3JT, UK *Corresponding author: E-mail: [email protected] http://ve.oxfordjournals.org/ Abstract Metagenomic studies are leading to the discovery of a hidden diversity of RNA viruses. These new viruses are poorly characterized and new approaches are needed predict the host species these viruses pose a risk to. The rhabdoviruses are a diverse family of RNA viruses that includes important pathogens of humans, animals, and plants. We have discovered thirty-two new rhabdoviruses through a combination of our own RNA sequencing of insects and searching public sequence databases. Combining these with previously known sequences we reconstructed the phylogeny of 195 rhabdovirus by guest on December 14, 2015 sequences, and produced the most in depth analysis of the family to date. In most cases we know nothing about the biology of the viruses beyond the host they were identified from, but our dataset provides a powerful phylogenetic approach to predict which are vector-borne viruses and which are specific to vertebrates or arthropods. -
Virus Replication
Introduction • Encompasses > 150 viruses Rhabdoviridae •Rabies –only important human Brian Wells pathogen • One of the most lethal of all infectious diseases History History • Adapted from Latin meaning “to rage” • 1885 – Louis Pasteur – rabies vaccine • Greeks – lyssa – “frenzy” – Attenuated form of virus produced by inoculation of rabbit spinal cord • Rabies represents one of the oldest and most feared diseases • Occurs throughout the world except in Australia, Japan, Great Britain, • Recognized in Egypt before 2300 B.C. and islands such as Hawaii • Well described by Aristotle • “Reportable” disease • Iliad – “canine madness” Taxonomy Viral Structure • 3 Genera – Ephemerovirus, Lyssavirus, • 170 nm x 70 nm Vesiculovirus • Bullet-shaped enveloped virion • Infect vertebrates, invertebrates, and – Glycoprotein peplomers & matrix protein plants under envelope • Genus Lyssavirus comprises rabies • Helical symmetry virus and 3 rabies-like viruses • Linear minus sense ssRNA – 11-12 kb • Each capable of causing rabies-like • Glycoprotein spikes in outer membrane disease in humans bilayer 1 Virus Replication • Receptor-mediated endocytosis • Uncoat and release nucleocapsid into cytoplasm • Production of 5 monocistronic mRNA species - N, P (NS), M, G, L – by L+P viral transcriptase • Each mRNA capped and poly-A’ed • dsRNA replicative intermediate Virus Replication Virus Replication • N+P+L and (-) ssRNA form core • M forms matrix around core • Virus buds from glycoprotein area of plasma membrane and thus acquires its envelope Transmission • Unstable -
Common COVID-19 Myths and Misinformation
Common COVID-19 Myths and Misinformation Myth: The side effects of Myth: The COVID-19 Myth: If I’ve already had the COVID-19 vaccine are vaccine can affect COVID-19, I don’t need a dangerous. women’s fertility. vaccine. Myth: Researchers rushed the development of the Myth: Getting the COVID- Myth: The COVID-19 COVID-19 vaccine, so its 19 vaccine gives you vaccine can affect effectiveness and safety COVID-19. women’s fertility. cannot be trusted. Myth: The COVID-19 vaccine enters your cells and changes your DNA. Information gathered from the following website: https://www.hopkinsmedicine.org/health/conditions-and-diseases/coronavirus/covid-19-vaccines-myth-versus-fact https://www.muhealth.org/our-stories/covid-19-vaccine-myths-vs-facts FACT: People who have gotten sick with COVID-19 may still benefit from getting vaccinated. Due to the severe health risks associated with COVID-19 and the fact that re-infection with COVID-19 is possible, people may be advised to get a COVID-19 vaccine If I’ve already had even if they have been sick with COVID-19 before. There is not enough information currently available to COVID-19, I don’t say if or for how long people are protected from getting COVID-19 after they have had it (natural need a vaccine. immunity). Early evidence suggests natural immunity from COVID-19 may not last very long, but more studies are needed to better understand this. Several subjects in the Pfizer trial who were previously infected got vaccinated without ill effects. Some scientists believe the vaccine offers better protection for coronavirus than natural infection. -
2020 Taxonomic Update for Phylum Negarnaviricota (Riboviria: Orthornavirae), Including the Large Orders Bunyavirales and Mononegavirales
Archives of Virology https://doi.org/10.1007/s00705-020-04731-2 VIROLOGY DIVISION NEWS 2020 taxonomic update for phylum Negarnaviricota (Riboviria: Orthornavirae), including the large orders Bunyavirales and Mononegavirales Jens H. Kuhn1 · Scott Adkins2 · Daniela Alioto3 · Sergey V. Alkhovsky4 · Gaya K. Amarasinghe5 · Simon J. Anthony6,7 · Tatjana Avšič‑Županc8 · María A. Ayllón9,10 · Justin Bahl11 · Anne Balkema‑Buschmann12 · Matthew J. Ballinger13 · Tomáš Bartonička14 · Christopher Basler15 · Sina Bavari16 · Martin Beer17 · Dennis A. Bente18 · Éric Bergeron19 · Brian H. Bird20 · Carol Blair21 · Kim R. Blasdell22 · Steven B. Bradfute23 · Rachel Breyta24 · Thomas Briese25 · Paul A. Brown26 · Ursula J. Buchholz27 · Michael J. Buchmeier28 · Alexander Bukreyev18,29 · Felicity Burt30 · Nihal Buzkan31 · Charles H. Calisher32 · Mengji Cao33,34 · Inmaculada Casas35 · John Chamberlain36 · Kartik Chandran37 · Rémi N. Charrel38 · Biao Chen39 · Michela Chiumenti40 · Il‑Ryong Choi41 · J. Christopher S. Clegg42 · Ian Crozier43 · John V. da Graça44 · Elena Dal Bó45 · Alberto M. R. Dávila46 · Juan Carlos de la Torre47 · Xavier de Lamballerie38 · Rik L. de Swart48 · Patrick L. Di Bello49 · Nicholas Di Paola50 · Francesco Di Serio40 · Ralf G. Dietzgen51 · Michele Digiaro52 · Valerian V. Dolja53 · Olga Dolnik54 · Michael A. Drebot55 · Jan Felix Drexler56 · Ralf Dürrwald57 · Lucie Dufkova58 · William G. Dundon59 · W. Paul Duprex60 · John M. Dye50 · Andrew J. Easton61 · Hideki Ebihara62 · Toufc Elbeaino63 · Koray Ergünay64 · Jorlan Fernandes195 · Anthony R. Fooks65 · Pierre B. H. Formenty66 · Leonie F. Forth17 · Ron A. M. Fouchier48 · Juliana Freitas‑Astúa67 · Selma Gago‑Zachert68,69 · George Fú Gāo70 · María Laura García71 · Adolfo García‑Sastre72 · Aura R. Garrison50 · Aiah Gbakima73 · Tracey Goldstein74 · Jean‑Paul J. Gonzalez75,76 · Anthony Grifths77 · Martin H. Groschup12 · Stephan Günther78 · Alexandro Guterres195 · Roy A. -
Characterization of Farmington Virus, a Novel Virus from Birds That Is Distantly Related to Members of the Family Rhabdoviridae
Palacios et al. Virology Journal 2013, 10:219 http://www.virologyj.com/content/10/1/219 RESEARCH Open Access Characterization of Farmington virus, a novel virus from birds that is distantly related to members of the family Rhabdoviridae Gustavo Palacios1†, Naomi L Forrester2,3,4†, Nazir Savji5,7†, Amelia P A Travassos da Rosa2, Hilda Guzman2, Kelly DeToy5, Vsevolod L Popov2,4, Peter J Walker6, W Ian Lipkin5, Nikos Vasilakis2,3,4 and Robert B Tesh2,4* Abstract Background: Farmington virus (FARV) is a rhabdovirus that was isolated from a wild bird during an outbreak of epizootic eastern equine encephalitis on a pheasant farm in Connecticut, USA. Findings: Analysis of the nearly complete genome sequence of the prototype CT AN 114 strain indicates that it encodes the five canonical rhabdovirus structural proteins (N, P, M, G and L) with alternative ORFs (> 180 nt) in the N and G genes. Phenotypic and genetic characterization of FARV has confirmed that it is a novel rhabdovirus and probably represents a new species within the family Rhabdoviridae. Conclusions: In sum, our analysis indicates that FARV represents a new species within the family Rhabdoviridae. Keywords: Farmington virus (FARV), Family Rhabdoviridae, Next generation sequencing, Phylogeny Background Results Therhabdovirusesarealargeanddiversegroupofsingle- Growth characteristics stranded, negative sense RNA viruses that infect a wide Three litters of newborn (1–2 day old) ICR mice with aver- range of vertebrates, invertebrates and plants [1]. The family agesizeof10pupswereinoculated intracerebrally (ic) with Rhabdoviridae is currently divided into nine approved ge- 15–20 μl, intraperitoneally (ip) with 100 μlorsubcutane- nera (Vesiculovirus, Perhavirus, Ephemerovirus, Lyssavirus, ously (sc) with 100 μlofastockofVero-grownFARV(CT Tibrovirus, Sigmavirus, Nucleorhabdovirus, Cytorhabdovirus AN 114) virus containing approximately 107 plaque and Novirhabdovirus);however,alargenumberofanimal forming units (PFU) per ml. -
Update on Approved and Candidate COVID-19 Vaccines in the EU
Update on approved and candidate COVID-19 vaccines in the EU Dr. Marco Cavaleri Head of Biological Health Threats and Vaccines Strategy, EMA An agency of the European Union Outline 1 EMA response to COVID-19 pandemic - milestones 2 COVID-19 vaccines approved in the EU 3 Benefits and risks of COVID-19 vaccines 4 Real world evidence on effectiveness 5 Studies in children 6 Vaccines under review by EMA 7 Adapting COVID-19 vaccines to variants 8 Additional information Classified as public by the European Medicines Agency EMA RESPONSE TO COVID-19 PANDEMIC Milestones in the fight against the pandemic Scientific & regulatory Rapid development & Transparency & mobilisation evaluation outreach Approval: Comirnaty, COVID-19 vaccine Moderna, COVID-19 vaccine AstraZeneca, COVID-19 vaccine Janssen Accelerated development & evaluation procedures WHO declares pandemic COVID-19 Experts’ Task Force Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec 2020 2021 1 Classified as public by the European Medicines Agency COVID-19 vaccines approved in the EU 4 vaccines authorised in the EU • Comirnaty and Moderna vaccines contain a molecule called messenger RNA (mRNA) with instructions for producing the spike protein from SARS-CoV-2, the virus that causes COVID-19 • The AstraZeneca and Janssen vaccine uses a non-replicating adenovirus as a carrier that has been modified to produce the spike protein from SARS-CoV-2. • The vaccines do not contain the SARS-CoV-2 virus causing COVID-19 itself and cannot cause the disease. Comirnaty COVID-19 Vaccine COVID-19 Vaccine COVID-19 Vaccine (BioNTech/Pfizer) Moderna AstraZeneca Janssen 21 Dec 6 Jan 29 Jan 11 Mar 2 Classified as public by the European Medicines Agency BENEFITS AND RISKS Efficacy of COVID-19 vaccines in trials All COVID-19 vaccines approved in the EU have a positive benefit-risk balance in prevention of COVID-19 disease. -
Characterizing and Evaluating the Zoonotic Potential of Novel Viruses Discovered in Vampire Bats
viruses Article Characterizing and Evaluating the Zoonotic Potential of Novel Viruses Discovered in Vampire Bats Laura M. Bergner 1,2,* , Nardus Mollentze 1,2 , Richard J. Orton 2 , Carlos Tello 3,4, Alice Broos 2, Roman Biek 1 and Daniel G. Streicker 1,2 1 Institute of Biodiversity, Animal Health and Comparative Medicine, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow G12 8QQ, UK; [email protected] (N.M.); [email protected] (R.B.); [email protected] (D.G.S.) 2 MRC–University of Glasgow Centre for Virus Research, Glasgow G61 1QH, UK; [email protected] (R.J.O.); [email protected] (A.B.) 3 Association for the Conservation and Development of Natural Resources, Lima 15037, Peru; [email protected] 4 Yunkawasi, Lima 15049, Peru * Correspondence: [email protected] Abstract: The contemporary surge in metagenomic sequencing has transformed knowledge of viral diversity in wildlife. However, evaluating which newly discovered viruses pose sufficient risk of infecting humans to merit detailed laboratory characterization and surveillance remains largely speculative. Machine learning algorithms have been developed to address this imbalance by ranking the relative likelihood of human infection based on viral genome sequences, but are not yet routinely Citation: Bergner, L.M.; Mollentze, applied to viruses at the time of their discovery. Here, we characterized viral genomes detected N.; Orton, R.J.; Tello, C.; Broos, A.; through metagenomic sequencing of feces and saliva from common vampire bats (Desmodus rotundus) Biek, R.; Streicker, D.G. and used these data as a case study in evaluating zoonotic potential using molecular sequencing Characterizing and Evaluating the data. -
Viral Zoonotic Encephalitis: Australian Bat Lyssavirus and Hendra
Viral zoonotic encephalitis: Australian Bat Lyssavirus and Hendra Bev Paterson Hunter© by Medicalauthor Research Institute University of Newcastle Australia ESCMID OnlineEmail: [email protected] Library Encephalitis in Australia Causes substantial morbidity and mortality Herpes simplex virus is the most commonly identified causative pathogen 70% of adult encephalitis hospitalisations no pathogen identified 57% of deaths no pathogen identified (Reference: Huppatz et al. CDI,© 2009; by Huppatzauthor et al. EID, 2009) ESCMID Online Lecture Library Viral zoonotic encphalitis Several recently emerged or resurging pathogens are known to cause an encephalitis syndrome Vectorborne and transmitted flaviviruses – MVEV, WNEV-KUN and JEV © by author Bat-borne viruses – Australian Bat Lyssavirus (ABLV) and Hendra virus ESCMID Online Lecture Library Impact of climatic conditions © by author ESCMID Online Lecture Library Australian Bat Lyssavirus Australia has no endemic rabies ABLV is a member of the family Rhabdoviridae, genus Lyssavirus ABLV is very closely related to rabies (genotype 7 of the Lyssavirus genus) Reservoir is bats © by author Two deaths from ABLV ESCMID Online Lecture Library Human exposure © by author ESCMID Online Lecture Library Epidemiology of human disease Two fatal human cases – coastal Qld – encephalitis indistinguishable from classic rabies 1996 – 39yr female, a few weeks after scratches from bat 1998 – 37yr female, 27 months after bite from bat © by author References (Samaratunga -
Statements Contained in This Release As the Result of New Information Or Future Events Or Developments
Pfizer and BioNTech Provide Update on Booster Program in Light of the Delta-Variant NEW YORK and MAINZ, GERMANY, July 8, 2021 — As part of Pfizer’s and BioNTech’s continued efforts to stay ahead of the virus causing COVID-19 and circulating mutations, the companies are providing an update on their comprehensive booster strategy. Pfizer and BioNTech have seen encouraging data in the ongoing booster trial of a third dose of the current BNT162b2 vaccine. Initial data from the study demonstrate that a booster dose given 6 months after the second dose has a consistent tolerability profile while eliciting high neutralization titers against the wild type and the Beta variant, which are 5 to 10 times higher than after two primary doses. The companies expect to publish more definitive data soon as well as in a peer-reviewed journal and plan to submit the data to the FDA, EMA and other regulatory authorities in the coming weeks. In addition, data from a recent Nature paper demonstrate that immune sera obtained shortly after dose 2 of the primary two dose series of BNT162b2 have strong neutralization titers against the Delta variant (B.1.617.2 lineage) in laboratory tests. The companies anticipate that a third dose will boost those antibody titers even higher, similar to how the third dose performs for the Beta variant (B.1.351). Pfizer and BioNTech are conducting preclinical and clinical tests to confirm this hypothesis. While Pfizer and BioNTech believe a third dose of BNT162b2 has the potential to preserve the highest levels of protective efficacy against all currently known variants including Delta, the companies are remaining vigilant and are developing an updated version of the Pfizer-BioNTech COVID-19 vaccine that targets the full spike protein of the Delta variant. -
Bat Rabies and Other Lyssavirus Infections
Prepared by the USGS National Wildlife Health Center Bat Rabies and Other Lyssavirus Infections Circular 1329 U.S. Department of the Interior U.S. Geological Survey Front cover photo (D.G. Constantine) A Townsend’s big-eared bat. Bat Rabies and Other Lyssavirus Infections By Denny G. Constantine Edited by David S. Blehert Circular 1329 U.S. Department of the Interior U.S. Geological Survey U.S. Department of the Interior KEN SALAZAR, Secretary U.S. Geological Survey Suzette M. Kimball, Acting Director U.S. Geological Survey, Reston, Virginia: 2009 For more information on the USGS—the Federal source for science about the Earth, its natural and living resources, natural hazards, and the environment, visit http://www.usgs.gov or call 1–888–ASK–USGS For an overview of USGS information products, including maps, imagery, and publications, visit http://www.usgs.gov/pubprod To order this and other USGS information products, visit http://store.usgs.gov Any use of trade, product, or firm names is for descriptive purposes only and does not imply endorsement by the U.S. Government. Although this report is in the public domain, permission must be secured from the individual copyright owners to reproduce any copyrighted materials contained within this report. Suggested citation: Constantine, D.G., 2009, Bat rabies and other lyssavirus infections: Reston, Va., U.S. Geological Survey Circular 1329, 68 p. Library of Congress Cataloging-in-Publication Data Constantine, Denny G., 1925– Bat rabies and other lyssavirus infections / by Denny G. Constantine. p. cm. - - (Geological circular ; 1329) ISBN 978–1–4113–2259–2 1. -
Borna Disease Virus Infection in Animals and Humans
Synopses Borna Disease Virus Infection in Animals and Humans Jürgen A. Richt,* Isolde Pfeuffer,* Matthias Christ,* Knut Frese,† Karl Bechter,‡ and Sibylle Herzog* *Institut für Virologie, Giessen, Germany; †Institut für Veterinär-Pathologie, Giessen, Germany; and ‡Universität Ulm, Günzburg, Germany The geographic distribution and host range of Borna disease (BD), a fatal neuro- logic disease of horses and sheep, are larger than previously thought. The etiologic agent, Borna disease virus (BDV), has been identified as an enveloped nonsegmented negative-strand RNA virus with unique properties of replication. Data indicate a high degree of genetic stability of BDV in its natural host, the horse. Studies in the Lewis rat have shown that BDV replication does not directly influence vital functions; rather, the disease is caused by a virus-induced T-cell–mediated immune reaction. Because antibodies reactive with BDV have been found in the sera of patients with neuro- psychiatric disorders, this review examines the possible link between BDV and such disorders. Seroepidemiologic and cerebrospinal fluid investigations of psychiatric patients suggest a causal role of BDV infection in human psychiatric disorders. In diagnostically unselected psychiatric patients, the distribution of psychiatric disorders was found to be similar in BDV seropositive and seronegative patients. In addition, BDV-seropositive neurologic patients became ill with lymphocytic meningoencephali- tis. In contrast to others, we found no evidence is reported for BDV RNA, BDV antigens, or infectious BDV in peripheral blood cells of psychiatric patients. Borna disease (BD), first described more predilection for the gray matter of the cerebral than 200 years ago in southern Germany as a hemispheres and the brain stem (8,19).